Showing 2481-2490 of 3134 results for "".
- Dr. Kelly Huang to Obalon; Alisa Lask to Oversee Galderma's Aesthetic & Corrective Business Unithttps://modernaesthetics.com/news/dr-kelly-huang-to-obalon-alisa-lask-to-oversee-galdermas-aesthetic-corrective-business-unit/2472202/Former Galderma general manager Kelly Huang, Ph.D. is now Obalon’s Chief Operating Officer. In this new role, Dr. Huang will be responsible for the key commercial functions of sales, marketing, operations, and quality assurance. In related
- Art Lesson Teaches Plastic Surgeons Better Botox Injection Techniqueshttps://modernaesthetics.com/news/art-lesson-teaches-plastic-surgeons-better-botox-injection-techniques-facebookshare-to/2472207/A highly detailed body painting project helps plastic surgeons understand how underlying muscles contribute to facial lines and wrinkles as well as how to better treat them using botulinum toxin injections. The illustrated article, which appears in Plas
- Bonti's Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://modernaesthetics.com/news/bontis-gateway-neuromodulator-performs-well-in-pase-2a-for-glabellar-lines/2472208/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serot
- Syneron Candela Becomes Private Company with Completion of Transaction with Funds Advised by Apax Partnershttps://modernaesthetics.com/news/syneron-candela-becomes-private-company-with-completion-of-transaction-with-funds-advised-by-apax-partners/2472211/Syneron Medical Ltd. announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transacti
- Neothetics, Inc.'s Stock Tumbles Following "Unambiguous" Negative LIPO-202 Resultshttps://modernaesthetics.com/news/neothetics-incs-stock-tumbles-following-unambiguous-negative-lipo-202-results/2472217/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares d
- Alma Lasers Inc. Hair Removal Platform Now Comprises Three Wavelengthshttps://modernaesthetics.com/news/alma-lasers-inc-hair-removal-platform-now-comprises-three-wavelengths/2472221/Alma Lasers now offers 1064 Nd: YAG capabilities along with 810nm and 755nm on its Soprano ICE platform, allowing users to better match wavelength to hair removal patient. Alma added Alexandrite technology to its Soprano ICE platform in 2014 for
- NJ Plastic Surgeon Dr. Barry Dibernardo To Lead ASERFhttps://modernaesthetics.com/news/nj-plastic-surgeon-barry-dibernardo-md-to-lead-aserf/2472233/New Jersey-based plastic surgeon Barry Dibernardo, MD is the new President of the Aesthetic Surgery Education And Research Foundation. ASERF is the philanthropic research and education arm of the American Society fo
- Read Their Lips: Avoid Unnatural Lip Enhancement Results With This Datahttps://modernaesthetics.com/news/read-their-lips-avoid-unnatural-lip-enhancement-results-with-this-data/2472247/Many a Real Housewife from Bravo’s hit reality TV franchise have been chastised for trout pout – or an overfilled, unnatural looking pucker. And now a new study, published by JAMA Facial
- Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefit in Phase 4 Studieshttps://modernaesthetics.com/news/restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit-in-phase-4-studies/2472251/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Breaking Business News: Apax Partners to Acquire Syneronhttps://modernaesthetics.com/news/breaking-business-news-apax-partner-to-acquire-syneron/2472253/An affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million. The per share acquisition price represe